Search Results 451-460 of 17463 for alopecia

1. Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the ...

2. CATALINA-2: A Clinical Study Of TORL-1-23 In Platinum-resistant Ovarian Cancer.

   ... alopecia or laboratory abnormalities otherwise meeting eligibility requirements. 2. Participants with clear cell, mucinous, sarcomatous (including ...

3. CAST-AI: Cystectomy after systemic therapy with ADC and Immunotherapy - Mayo Clinic

   ... alopecia) or conditions requiring hormonal replacement therapies such as type 1 diabetes mellitus or hypothyroidism are permitted to enroll * Known ...

4. Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant - Mayo Clinic

   Exception to this criterion: participant with any grade of alopecia are allowed to enter in the study. Participant with Child Pugh score B or C. Participant ...

5. A Study to Compare Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients - Mayo Clinic

   Patients with vitiligo or alopecia Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement Any chronic skin ...

6. Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma - Mayo Clinic

   Toxicities due to prior therapy must be stable and recovered to Grade ≤ 1 (except for clinically nonsignificant toxicities such as alopecia). Age 18 or ...

7. A Study to Compare the Effectiveness and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) - Mayo Clinic

   Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 peripheral neuropathy. Exclusion ...

8. Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer - Mayo Clinic

   ... alopecia and peripheral neuropathy. Have adequate organ function, including: Hematologic: absolute neutrophil count ≥1.5 × 10⁹/Liter (L), platelets ≥100 ...

9. Mayo Clinic

   ... . VID-20177817. Home; YouTube-Pulmonary Tests PFT Chest CT Flexible Bronchoscopy. 3X your impact! Give Now! Your gift can go 3X as far to shape the ...

10. A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer - Mayo Clinic

    ... alopecia, radiation tissue fibrosis, or peripheral neuropathy) * Known allergies, hypersensitivity, or intolerance to JNJ-69086420 or its excipients and ...